Drug Profile
Research programme : type II diabetes therapeutics - Sanofi
Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Class Peptides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in USA (PO) (Sanofi pipeline, October 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 23 Jan 2017 Sanofi in-licenses Peptelligence™ drug delivery platform technology from Enteris BioPharma